Header

UZH-Logo

Maintenance Infos

A novel anti-melanoma SRC-family kinase inhibitor


Halaban, Ruth; Bacchiocchi, Antonella; Straub, Robert; Cao, Jian; Sznol, Mario; Narayan, Deepak; Allam, Ahmed; Krauthammer, Michael; Mansour, Tarek S (2019). A novel anti-melanoma SRC-family kinase inhibitor. OncoTarget, 10(23):2237-2251.

Abstract

The major drawback of melanoma therapy with BRAF and MAPK inhibitors is the innate and acquired drug resistance. We therefore explored alternative targets and developed a new compound, SAB298, that is a SRC-family kinase (SFK) inhibitor. The drug is cytotoxic to patient-derived melanoma cells regardless of oncogene expression and inhibits tumor growth in vivo. As expected, it inhibited SRC and PI3K activity, and had the additional property of ERBB2 inhibition, that lead to inactivation of the two ERK phosphatases PP2A and SHP2. In 57% of the melanoma cell lines tested, the consequent increase in ERK activity lead to proteolytic degradation of its substrate, the lineage specific transcription factor MITF, likely contributing to growth arrest. Treatment with a combination of SAB298 and AZD6244 (selumetinib), induced a synergistic growth inhibition, suggesting that the new compound could be used in the clinic as a substitute for, or in combination with MAPK inhibitors.

Abstract

The major drawback of melanoma therapy with BRAF and MAPK inhibitors is the innate and acquired drug resistance. We therefore explored alternative targets and developed a new compound, SAB298, that is a SRC-family kinase (SFK) inhibitor. The drug is cytotoxic to patient-derived melanoma cells regardless of oncogene expression and inhibits tumor growth in vivo. As expected, it inhibited SRC and PI3K activity, and had the additional property of ERBB2 inhibition, that lead to inactivation of the two ERK phosphatases PP2A and SHP2. In 57% of the melanoma cell lines tested, the consequent increase in ERK activity lead to proteolytic degradation of its substrate, the lineage specific transcription factor MITF, likely contributing to growth arrest. Treatment with a combination of SAB298 and AZD6244 (selumetinib), induced a synergistic growth inhibition, suggesting that the new compound could be used in the clinic as a substitute for, or in combination with MAPK inhibitors.

Statistics

Citations

Dimensions.ai Metrics

Altmetrics

Downloads

19 downloads since deposited on 20 Jan 2020
11 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:07 Faculty of Science > Department of Quantitative Biomedicine
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Oncology
Uncontrolled Keywords:Oncology
Language:English
Date:19 March 2019
Deposited On:20 Jan 2020 10:44
Last Modified:22 Apr 2020 22:28
Publisher:Impact Journals, LLC
ISSN:1949-2553
OA Status:Green
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.18632/oncotarget.26787

Download

Green Open Access

Download PDF  'A novel anti-melanoma SRC-family kinase inhibitor'.
Preview
Content: Published Version
Filetype: PDF
Size: 8MB
View at publisher
Licence: Creative Commons: Attribution 3.0 Unported (CC BY 3.0)